H|T: The Healthtech Times – Ontario budget allocates funding to healthtech procurement
Plus: Neuralink is now accepting Canadian patients.
Source: betakit.com
📰 Immune Profiler News
Immune Profiler News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immune Profiler. Real-time updates on events, politics, business and more.
Georgiamune and Verily Partner to Advance Novel Cancer Treatment
Georgiamune and Verily forms a strategic partnership to advance novel therapeutics for patients with cancer.
Samirn Khleif Should Know Clinical Trial Data Longitudinal Real World Data Immune Profiler Chief Executive Officer
Source: hitconsultant.net
Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development
Nomination of novel drug target based on insights generated through application of Verily’s Immune Profiler platform and Sosei Heptares’ GPCR-focused structure-based drug design expertise ...
Source: marketscreener.com
Verily and Kyverna Therapeutics Announce Collaboration to Advance Cell Therapy for Autoimmune Diseases
/PRNewswire/ -- Verily, an Alphabet precision health technology company, and Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company...
Source: prnewswire.com
One Verily Forward | Verily Life Sciences
This is an important day for Verily, as we announce our refined strategy, prioritized portfolio and simplified operating model. This is work...
Source: verily.com
Alphabet's Verily raises $1B to expand precision health business
Alphabet's life science arm also announces the company's founder Andy Conrad will step down as CEO. Current president Stephen Gillett will take on the role in January.
Source: mobihealthnews.com
NEC OncoImmunity Develops Personalized HLA Typing Tool to Guide Cancer Immunotherapy
The Norwegian firm is incorporating the tool into ongoing research projects, including clinical trials, via its Immune Profiler platform.
Trevor Clancy Espen Basmo Ellingsen Broad Institute Society For Immunotherapy Of Cancer Columbia University Response Genetics
Source: genomeweb.com
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseasesResearch agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug desi...
United Kingdom Matt Barnes Sosei Heptares Jessica Mega Sosei Heptare Sosei Group Corporation Heptares
Source: pharmiweb.com
Sosei Heptares and Verily to collaborate on immune-mediated disease treatments
The companies share the goal of furthering knowledge around GPCR biology in immune cells in order to better understand a range of immune system disorders. - News - PharmaTimes
Matt Barnes Sosei Heptares Jessica Mega Sosei Group Corporation Group Corporation Sosei Heptareg Protein Coupled
Source: pharmatimes.com
Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases
New research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform,
Sosei Heptares Sosei Heptares Collaborate Generate Novel Drug Candidates Against Should Know Immune Profiler
Source: hitconsultant.net